Recent News

• 12.10.2025 - IceCure's ProSense® Cryoablation Featured in 4 Independent Breast Cancer Studies Presented at Radiological Society of America 2025 Annual Meeting
• 12.05.2025 - IceCure Receives Notice of Patent Allowance in China for a Novel Cryogen Flow Control to Optimize Patient Cryoablation Outcomes
• 11.19.2025 - IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025
• 11.18.2025 - IceCure's ProSense® Cryoablation System Receives Regulatory Approval in Switzerland for Indications Including Breast, Lung, Liver, and Kidney Cancer
• 11.14.2025 - IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification
• 11.12.2025 - IceCure Medical to Report Third Quarter 2025 Financial and Operating Results on November 19, 2025
• 11.10.2025 - IceCure Promotes Shay Levav to Chief Operating Officer as Company Ramps up for Increased Commercial Traction
• 11.03.2025 - IceCure's Cryoablation System Combined with Radiation Therapy Successfully Treats Non-Small Cell Lung Cancer (NSCLC) with 92% Disease-Specific 5-year Survival

Recent Filings

• 12.05.2025 - EX-99.1 EX-99.1
• 12.05.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 12.03.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 12.03.2025 - EX-99.1 EX-99.1
• 11.19.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 11.19.2025 - EX-99.1 EX-99.1
• 11.18.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 11.18.2025 - EX-99.1 EX-99.1
• 11.14.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 11.14.2025 - EX-99.1 EX-99.1